Prevalence of autoimmune diabetes among Aboriginal Australians: the Fremantle Diabetes Study Phase II.

Timothy M E Davis, Christine S Bundell, Stephen A Paul Chubb, Daniel McAullay, Wendy A Davis

Abstract read

In one paragraph

Article in Internal medicine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Timothy M E DavisMedical School, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia.ORCID 0000-0003-0749-7411

Christine S BundellDepartment of Clinical Immunology, PathWest Laboratory Medicine, QEII Medical Centre, Perth, Western Australia, Australia.

Stephen A Paul ChubbDepartment of Biochemistry, PathWest Laboratory Medicine, Fiona Stanley Hospital, Perth, Western Australia, Australia.

Daniel McAullayKurongkurl Katitjin, Centre for Indigenous Australian Education and Research, Edith Cowan University, Perth, Western Australia, Australia.

Wendy A DavisMedical School, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia.ORCID 0000-0002-5709-8235

Funding

National Health and Medical Research Council 1042231National Health and Medical Research Council 513781

6 · The paper itself

Abstract

The prevalence of autoimmune diabetes was assessed in 113 indigenous and 1555 non-indigenous participants in the Fremantle Diabetes Study Phase II. Both type 1 diabetes (3.5% vs. 8.2%) and latent autoimmune diabetes of adults diagnosed based on glutamic acid decarboxylase antibody (GADA) positivity (1.0% vs. 5.7%) were lower in Aboriginal participants (P = 0.101 and 0.039 respectively). Six Aboriginals with GADA-negative type 2 diabetes were positive for tyrosine phosphatase-related islet antigen 2 antibodies but did not exhibit relative insulin deficiency.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2AdultAustraliaAutoantibodiesFemaleGlutamate DecarboxylaseHumansLatent Autoimmune Diabetes in AdultsMaleMiddle AgedPrevalenceYoung AdultAutoantibodiesGlutamate Decarboxylaseautoimmune diabetesindigenouslatent autoimmune diabetes of adultsprevalencetype 1 diabetes

Identifiers

PMID40099758

DOI10.1111/imj.70029

PMCPMC11981027

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.